NasdaqGM - Nasdaq Real Time Price USD

Apogee Therapeutics, Inc. (APGE)

Compare

44.50

+0.18

(+0.41%)

At close: December 13 at 4:00:02 PM EST

44.94

+0.44

(+0.99%)

After hours: December 13 at 7:15:03 PM EST

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus monotherapy Preclinical proof-of-concept achieved for APG777 + APG333 combination with clinical trial planning underway in asthma and COPD SAN FRANCISCO and WALTHAM, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing nove

GlobeNewswire 5 days ago

APGE
+0.41%
Apogee Therapeutics Advances in I&I Disease Treatments

Apogee Therapeutics, Inc. ( (APGE) ) just unveiled an announcement. Apogee Therapeutics is making significant strides in its biologic programs for inflammatory and immunology (I&I) diseases. The company is showcasing promising data from its APG808 and APG777 trials, indicating potential for less frequent dosing and enhanced treatment efficacy. APG777, in particular, shows potential for annual dosing in atopic dermatitis, a vast market opportunity. Furthermore, the company is advancing combinatio

TipRanks 12 days ago

APGE
+0.41%
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers Data up to 12 months reinforce APG777’s best-in-class potential, including 77-day half-life, and provide a potential path to annual dosing 16-week topline data from APG777 Phase 2 Part A trial in AD accelerated to mid-2025 based on strong enrollment Preclinical and coformulation proof

GlobeNewswire 13 days ago

APGE
+0.41%
Apogee Therapeutics Announces Agenda for Virtual R&D Day

SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Mon

GlobeNewswire 16 days ago

APGE
+0.41%
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatmentsSAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic derm

GlobeNewswire 27 days ago

APGE
+0.41%
Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Apogee...

Simply Wall St. last month

APGE
+0.41%
Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028

As of September 30, 2024, Apogee had cash, cash equivalents and marketable securities of $753.8 million. Apogee expects that its existing cash will enable it to fund its current operating expenses into the first quarter of 2028. “We continue to execute across our portfolio and advance potentially transformative therapies for patients living with I&I diseases by positioning our pipeline to achieve potential best-in-class efficacy and dosing,” said Michael Henderson, M.D., Chief Executive Officer

TipRanks last month

APGE
+0.41%
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results

Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2 Part A data for APG777 in 2H 2025, interim Phase 1 data for APG808 in 4Q 2024 and interim Phase 1 data for APG990 in 1H 2025 APG333 development candidate selected and accelerating initiation of Phase 1 in late 2024 or early 2025; potential to offer best-in-class combination efficacy across multiple resp

GlobeNewswire last month

APGE
+0.41%
Apogee Therapeutics to Participate in Upcoming November Investor Conferences

SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management will participate at the following

GlobeNewswire last month

APGE
+0.41%
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases

Pharmacokinetic data up to 9 months continue to support potential best-in-class profile, including a half-life of approximately 75 days, approximately three to five times that of currently approved treatments for moderate-to-severe AD Key biomarker data from single doses of APG777 show near complete inhibition of pSTAT6 and sustained TARC inhibition up to 9 months Proof-of-concept data from the ongoing APG777 Phase 2 clinical trial in patients with moderate-to-severe atopic dermatitis are expect

GlobeNewswire last month

APGE
+0.41%
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced an upcoming poster presentation at the American College of Al

GlobeNewswire last month

APGE
+0.41%
Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now

We recently compiled a list of the 10 Best Hot Stocks To Buy Right Now. In this article, we are going to take a look at where Apogee Therapeutics, Inc. (NASDAQ:APGE) stands against the other hot stocks. While the market is seeing significant positives after the Fed rate cut, there have been some pressures. For example, […]

Insider Monkey 2 months ago

APGE
+0.41%
Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc

Wellington Management Group LLP, a prominent investment management firm, recently expanded its portfolio by acquiring an additional 1,267,451 shares of Apogee Therapeutics Inc (NASDAQ:APGE). This transaction, which took place on September 30, 2024, significantly increased Wellington's holdings in the biotechnology company, bringing the total to 4,814,400 shares. The shares were purchased at a price of $58.74 each, reflecting a strategic move by the firm to bolster its position in the healthcare sector.

GuruFocus.com 2 months ago

APGE
+0.41%
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management, will participate in a fireside c

GlobeNewswire 3 months ago

APGE
+0.41%
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr.

GlobeNewswire 3 months ago

APGE
+0.41%
Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE)

The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 280,793 shares of Apogee Therapeutics Inc. Apogee Therapeutics Inc (NASDAQ:APGE) is a biopharmaceutical company focused on the development and commercialization of novel therapies to treat autoimmune and inflammatory diseases.

GuruFocus.com 3 months ago

APGE
+0.41%
Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)

The transaction was documented in an SEC Filing. Following this sale, the insider now owns 200,871 shares of Apogee Therapeutics Inc. Apogee Therapeutics Inc is engaged in the development and commercialization of various therapies aimed at treating diseases with significant unmet medical needs.

GuruFocus.com 3 months ago

APGE
+0.41%
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025 with the potential for greater efficacy in atopic dermatitis and across I&I diseases SAN FRANCISCO and WALTHAM, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated effica

GlobeNewswire 3 months ago

APGE
+0.41%
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data from the Phase 2 Part A trial in 2H 2025, APG808 interim Phase 1 data in 4Q 2024, and APG990 Phase 1 trial initiation in healthy volunteers accelerated to 3Q 2024 APG333, a novel subcutaneous half-life extended anti-TSLP antibody, added to portfolio to provide for potential best-in-class combination efficacy across multiple respiratory indications, expected to enter the cli

GlobeNewswire 4 months ago

APGE
+0.41%
Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares

The transaction was disclosed in a recent SEC Filing. Apogee Therapeutics Inc is engaged in the development and commercialization of various therapies aimed at treating diseases with significant unmet medical needs. Over the past year, Michael Henderson has sold a total of 55,000 shares and has not made any purchases of stock in the company.

GuruFocus.com 4 months ago

APGE
+0.41%

Performance Overview

Return	APGE	S&P 500
YTD	+59.27%	+26.86%
1-Year	+108.63%	+30.31%
3-Year	+106.98%	+28.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

Apogee Therapeutics Advances in I&I Disease Treatments

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Apogee Therapeutics Announces Agenda for Virtual R&D Day

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans

Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now

Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE)

Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares

Performance Overview